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Abstract
Background: Alveolar macrophages are professional phagocytes that remove microbial pathogens inhaled into the
lung. The phagocytic ability is compromised in chronic obstructive pulmonary disease (COPD). However, the
molecular mechanisms underlying this defect in phagocytosis are not clearly defined.
Materials and methods: Cell suspensions were collected from lung tissues of patients undergoing lung resection.
Alveolar macrophages were detected as FSChi/ SSChi/CD45+/CD206+ cells in the isolated cell suspension by flow-
cytometry. The cell surface expression of plasma membrane-bound phagocytic receptors (Fcγ receptor I (FcγRI), a
complement receptor CD11b, macrophage scavenger receptor-1 (MSR-1), CD36 and Siglec-1) was determined on
the alveolar macrophages. Correlations between the expression levels of the phagocytic receptors and disease
severity were analysed. Phagocytosis of fluorescence-tagged bacteria by human alveolar macrophages was
evaluated.
Results: The flow-cytometry analyses revealed that FcγRI, CD11b, MSR-1 and Siglec-1, but not CD36, were
expressed on human alveolar macrophages. Among these receptors, Siglec-1 expression was significantly decreased
on alveolar macrophages in COPD ex-smokers (n = 11), compared to control never-smokers (n = 11) or control ex-
smokers (n = 9). The Siglec-1 expression on alveolar macrophages was significantly correlated with lung function
(forced expiratory volume in 1 s) and with the severity of emphysema. Treatment of human alveolar macrophages
with an anti-Siglec1 blocking antibody decreased phagocytosis of non-typeable Haemophilus influenzae (NTHi).
Conclusion: Our findings demonstrated reduced expression of Siglec-1 on alveolar macrophages in COPD, which is
involved in engulfment of NTHi.
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Background
Alveolar macrophages serve as professional phagocytes
that have the ability to eliminate inhaled microorganisms
or noxious particles and endogenous apoptotic cells or
cellular debris for innate host defence and the resolution
of inflammation [1]. However, in the lung of patients
with chronic obstructive pulmonary disease (COPD), al-
veolar macrophages participate in pathological processes
of chronic inflammation and tissue remodelling (i.e. al-
veolar destruction and small airway fibrosis) by produ-
cing reactive oxygen species (ROS), pro-inflammatory
cytokines/chemokines, elastolytic proteases and pro-
fibrotic mediators [2, 3]. In addition to the dysregulated
production of the mediators, recent studies have
indicated that alveolar macrophages of COPD were
functionally defective in the phagocytosis of microbial
pathogens, such as Haemophilus influenzae [4–6],
Streptococcus pneumoniae [5] and Moraxella catarrhalis
[6]. This defective phagocytosis of microbes is implicated
in the bacterial colonisation and persistent inflammation
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in the airway of COPD, which are postulated to cause
acute exacerbations [7].
Phagocytosis is defined as the cellular uptake of parti-
cles (> 0.5 μm) by a plasma-membrane envelope and
consists of multiple biological processes: recognition,
engulfment, plasma-membrane fusion, maturation of
phagosomes with progressive acidification and culminat-
ing in phagolysosomal fusion and digestion [8]. Plasma
membrane-receptors have a critical role in the sensing
and engulfment of microbes in the initial phase of
phagocytosis and are classified into (i) opsonic receptors
(Fc receptors and complement receptors) and (ii) non-
opsonic, pattern-recognition receptors (scavenger recep-
tors and lectin-like recognition molecules) [9]. Scavenger
receptors such as macrophage scavenger receptor-1
(MSR-1, also known as SR-A1), macrophage receptor
with collagenous structure (MARCO, also known as SR-
A2) and CD36 vary in the structure of their extracellular
domains and recognise a large variety of molecules in-
cluding not only microbial ligands (lipopolysaccharide
and lipoteichoic acid) but also endogenous self-ligands
(lipoproteins, unmodified proteins, etc.) [10]. Lectin-like
recognition molecules also consist of diverse membrane-
bound receptors such as C-type lectin receptors (man-
nose receptor or dectin-1, etc.) and sialic acid-binding
immunoglobulin-like lectins (e.g. Siglec-1) [11]. This ex-
tremely diverse array of plasma membrane-receptors al-
lows professional phagocytes to sense and eat a wide
variety of foreign pathogens.
It is known that the expression of cell surface mole-
cules is altered in alveolar macrophages of smokers or
patients with COPD. Smoking reduces the expression of
cell surface molecules involved in apoptotic cell-
clearance (CD91) and cellular adhesion (CD31, CD44)
[12]. Moreover molecules involved in antigen presenta-
tion (CD86 and CD11a) are down-regulated in the al-
veolar macrophages of COPD [13]. Despite the
increasing evidence of the phenotypic alteration of al-
veolar macrophages under a pathological condition, the
expression levels of receptors mediating bacterial phago-
cytosis have not been clearly determined.
In this study, we aimed to determine alteration of ex-
pression levels of phagocytosis-associated receptors in
COPD and its functional consequences in bacterial up-
take. Here we analysed representative membrane-bound
receptors that are known to be involved in bacteria
phagocytosis including Fcγ receptor I (FcγRI), CD11b (a
subset of a complement receptor), MSR-1, CD36 and
Siglec-1 (also knonwn as CD169). We directly analysed
the cell surface expression of these receptors on alveolar
macrophages freshly isolated from human lung tissues
using flow-cytometry and found that Siglec-1 expression
was significantly decreased in alveolar macrophages iso-
lated from lung tissues of patients with COPD.
Furthermore we confirmed that a blocking antibody for
Siglec-1 reduced the phagocytosis capability of non-




Subjects for the flow-cytometric analysis and immuno-
staining of phagocytic receptor expression participated
in the study from September 2016 to August 2017. Sub-
jects for the phagocytosis study participated between
January 2018 to August 2019. All patients with COPD
satisfied the Global Initiative for Chronic Obstructive
Lung Disease (GOLD) guideline criteria [14]. Control
ex-smokers and COPD ex-smokers had ceased smoking
for more than 2 months before the enrolment. We ex-
cluded current smokers and subjects with asthma, bron-
chiectasis, pulmonary fibrosis or other inflammatory
lung diseases. Written informed consent was obtained
from all subjects who participated in this study. This
study was approved by the ethics committees at Tohoku
University School Graduate of Medicine (registration
number: 2017–1-352) and Japanese Red Cross Ishino-
maki Hospital (registration number: 13–12).
Chest CT assessment of low attenuation areas
We evaluated low attenuation area scores using a high-
resolution CT scan as an indicator for pulmonary em-
physema according to the Goddard classification [15].
Briefly low attenuation value was scored for the bilateral
upper, middle and lower lung fields. Zero represented
no emphysema; 1 was given for up to 25%, 2 for up to
50%, 3 for up to 75% and 4 for total involvement or al-
most total absence of normal lung tissues. Scores ranged
from 0 to 24.
Preparation of lung cell suspension
Lung tissues were provided by patients who underwent
lung resection due to primary lung cancer. We verified
that the tissues had no pathological findings of tumours
or overt fibrosis. Resected lung tissues were immediately
immersed in StemSurvive-Lung tissue preservation solu-
tion (Kurabo Industries Ltd., Osaka, Japan), stored at
4 °C and used within 12 hours after surgery.
Flow-cytometry analysis, fluorescence-activated cell
sorting and diff-Quik staining
We collected lung hematopoietic cells including alveolar
macrophages by perfusing and lavaging tissues with sa-
line. Detailed methods for flow-cytometric analyses were
described in the online supplement.
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Preparation of heat-killed and fluorescent dye-tagged
non-typeable Haemophilus influenzae
Non-typeable Haemophilus influenzae (NTHi; GTC
15013, JNBP_02694) was obtained from Gifu University
Center for Conservation of Microbial Genetic Resource.
The number of bacteria was counted with Bacteria
Counting Kit (Thermo Fisher Scientific). NTHi was
killed at 65 °C for 1 hour and was labeled with pHrode
Phagocytosis Particle Labeling Kit for Flow Cytometry
(Thermo Fisher Scientific) according to the manufac-
turer’s instruction.
Phagocytosis assay
Lung tissue was perfused with normal saline. The re-
trieved cell suspension was centrifuged at 400 g for 30
min at 20 °C. Cellular fractions in the cell suspensions
were routinely evaluated by Diff-Quik staining. The cell
pellet was resuspended in PBS and subjected to Ficoll-
Paque (GE Healthcare) density gradient centrifugation to
remove granulocytes and erythrocytes. The mononuclear
cell layer at the interface, mainly containing alveolar
macrophages, was collected and washed with PBS. 6 ×
105 cells were reconstituted into 2 mL of HEPES-
buffered RPMI 1640 (Thermo Fisher Scientific) contain-
ing 1% IgG/protease-free BSA. 3 × 104 cells in 100 μL of
the cell suspension were transferred into each well of a
96 well formatted plate and incubated for 2 hours in the
5% CO2 incubator at 37 °C. Anti-human Siglec-1 block-
ing antibody (BIO-RAD, clone 7–239, cat#
MCA2517EL) or an isotype-matched control antibody
(mouse IgG1; BIO-RAD, cat# MCA 928EL) was added
and incubated for 1 hour at room temperature in order
to block Siglec-1 on the surface of alveolar macrophages
[16]. The final concentration of these antibodies was
10 μg/mL, which was sufficient to block binding of add-
itional phycoerythrin-conjugated anti-human Siglec-1
antibody (eBioscience, clone 7–239, cat# 12–1699-42).
This concentration of the antibody was not influential in
cell viability (data not shown). Heat-killed and pHrode-
labeled NTHi at 100 MOI was added onto the culture
media. After 1 hour, cells were collected with 0.5% Tryp-
sin/EDTA. Positive cells that engulfed pHrode-labeled
bacteria in acidic phagosome compartments were quan-
tified by flow-cytometry using FACS CantoII (BD Biosci-
ences). Data were analysed by FlowJo (Tree Star Inc.,
OR, USA).
Statistics
All data are expressed as medians (with interquartile
ranges) unless otherwise indicated. Statistical tests were
performed using GraphPad Prism 8 (GraphPad Soft-
ware Inc., CA, USA). Difference in the distribution of
the genders between CNS, CES and COPD were ana-
lysed using the Chi square test. For comparison
between three groups, the Kruskal-Wallis test followed
by the Dunn’s multiple comparison test was per-
formed. Statistical correlation analyses were performed
using Spearman’s test. Multivariable regression analyses
were performed for evaluating the effect of potentially
confounding factors. P-values less than 0.05 were con-
sidered significant.
Results
Characterisation of phagocytosis-associated receptor
expression on alveolar macrophages isolated from lung
tissues of patients with COPD
To examine cell surface expression levels of
phagocytosis-associated receptors on human alveolar
macrophages, we collected cell suspension by perfusing
and lavaging peripheral lung tissues with saline and de-
lineated alveolar macrophages as FSChi/SSChi/CD45+/
CD206+ cells in flow-cytometry according to previous
studies [2, 3] (Fig. 1a). We confirmed that FSChi/SSChi/
CD45+/CD206+ cells from human lung tissue lavage
were alveolar macrophages in three ways. First, cytospin
samples of sorted FSChi/SSChi/CD45+/CD206+ cells ex-
hibited homogenous, basophilic large cells that were
morphologically consistent with alveolar macrophages
(Additional file 1: Figure S1A). Second, immunohisto-
chemistry verified that CD206 was expressed by alveolar
macrophages in human lung sections and its expression
pattern was not different between control never-smokers
(CNS), control ex-smokers (CES) and COPD ex-smokers
(COPD) (Additional file 1: Figure S1B). Third, FSChi/
SSChi/CD45+/CD206+ cells expressed CD14 at a mini-
mum level, which was consisting with the previous re-
ports [2, 3] (Additional file 1: Figure S1C).
We then examined the expression of each of
phagocytosis-associated receptors (FcγRI, CD11b,
MSR-1, CD36 and Siglec-1) on the surface of FSChi/
SSChi/CD45+/CD206+ alveolar macrophages in flow-
cytometry, that were collected from lung tissues of
CNS (n = 11), CES (n = 9) and COPD with mild-to-
moderate airflow limitation severity (n = 5 in GOLD
stage1, n = 6 in GOLD stage2). The patient characteris-
tics in the flow-cytometric analysis are shown in
Table 1. We evaluated the receptor expression by two
parameters: (i) the percentage of alveolar macrophages
expressing each of the receptors to total alveolar mac-
rophages and (ii) the geometric mean of the receptor
expression intensity normalised by that of a corre-
sponding fluorochrome minus one (FMO) control with
an appropriate isotype control antibody. We found
that FcγRI, CD11b, MSR-1 and Siglec-1 were
expressed by alveolar macrophages isolated from CNS
but CD36 exhibited no or little expression (Fig. 1b).
The percentage of alveolar macrophages expressing
FcγRI or Siglec-1 was significantly decreased in COPD
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subjects compared to CNS and CES (Fig. 2a). More-
over the percentage of alveolar macrophages express-
ing MSR-1 was slightly decreased in COPD subjects
compared to CES, although its decrease was significant
between COPD and CNS (Fig. 2a). Among these re-
ceptors, the reduction of Siglec-1 expression intensity
on alveolar macrophages of COPD patients was statis-
tically significant compared to CNS and CES (Fig. 2b).
Although the difference in the expression intensity of
FcγRI and MSR-1 of between CES and COPD was not
statistically significant, the intensity of these receptors
was decreased in COPD compared to CNS (Fig. 2b).
Relationship between phagocytosis-associated receptor
expression on alveolar macrophages and clinical variables
Considering the differences in the expression level of
FcγRI, MSR-1 and Siglec-1 on alveolar macrophages be-
tween CNS, CES and COPD, we next sought to deter-
mine whether these differences were associated with
clinical variables such as age, gender, smoking history,
airflow limitation severity and pulmonary emphysema.
The severity of airflow limitation was evaluated as % pre-
dicted values of forced expiratory volume in 1 second
(FEV1%pred). Pulmonary emphysema was quantified by
measuring low attenuation areas on chest computed
Fig. 1 Expression levels of phagocytic receptors on human alveolar macrophages. a FACS gating strategy to delineate alveolar macrophages. Cell
suspension was collected by perfusing and lavaging human lung tissues with saline. Alveolar macrophages were detected as live, FSChi/SSChi,
single cell-gated CD45+/CD206+ cells in the cell suspension. b Representative histograms for the expression levels of FcγRI, CD11b, macrophage
scavenger receptor-1 (MSR-1), CD36 and Siglec-1, on FSChi/SSChi/CD45+/CD206+ alveolar macrophages of control never-smokers (CNS, n = 11),
control ex-smokers (CES, n = 9) and COPD ex-smokers (COPD, n = 11). Specific staining, open; isotype control, shaded
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tomography (CT) images. We found that smoking his-
tory, FEV1%pred and low attenuation area scores exhib-
ited a significant association with the phagocytosis-
associated receptor expression (Table 2). A multiple lin-
ear regression analysis revealed that the severity of pul-
monary emphysema was independently associated with
the reduction of Siglec-1 expression on alveolar macro-
phages (Table 3).
Siglec-1 was important for engulfment of non-typeable
Haemophilus influenzae by human alveolar macrophages
So far we observed the significant reduction of Siglec-
1 protein expression on alveolar macrophages of
patients with COPD. Siglec-1 is known to recognise
sialylated bacteria such as Neisseria meningitidis [17].
Considering that non-typeable Haemophilus influenzae
(NTHi) was a sialylated pathogen and was mainly
associated with exacerbation and bacterial colonisation
of COPD, we therefore sought to determine whether
Siglec-1 was functionally important for uptake of
NTHi by human alveolar macrophages. As we wished
to evaluate how Siglec-1 affected engulfment at the
initial stage of bacterial phagocytosis, but not microbi-
cidal efficacy in the late stage, we used heat-killed,
fluorescent dye-tagged NTHi that increased in fluores-
cence under an acidic condition in phagolysosomes.
We evaluated alveolar macrophages isolated from con-
trol never smokers that expressed Siglec-1 as shown
by immunohistochemistry (Additional file 1: Figure
S2). The patients’ characteristics was shown in Table 4.
Cellular fractions of collected cell suspensions were as
follows: macrophages, 89.0 ± 2.3%; lymphocytes, 6.2 ±
2.0%; neutrophils, 3.8 ± 1.5%; eosinophils, 0.4 ± 0.3%;
monocytes, 0.8 ± 0.3%. After density gradient centrifu-
gation to remove granulocytes, mononuclear cells were
seeded on culture plates, most of which were thought
to be alveolar macrophages. Then, adherent cells were
cultured in the presence of an anti-Siglec-1 blocking
antibody to inhibit biding of bacteria to Siglec-1 or an
isotype-matched control antibody, which was followed
Table 1 Patient characteristics in flow-cytometry analyses and immunohistochemistry results of phagocytic receptor expression of
alveolar macrophages
Control never-smokers Control ex-smokers COPD ex-smokers
Subjects (n) 11 9 11
Men/women 1/10 7/2*** 11/0****
Age 72 (64.0–77.0) 75 (65.5–77.5) 67 (64.0–73.0)
Smoking (pack-years) 0.0 (0.0–0.0) 33.0 (18.3–49.1)** 43.0 (30.0–68.8)****
Duration of smoking cessation (months) NA 48.0 (2.0–168.0) 12.0 (2.0–120.0)
FVC (%pred) 100.7 (94.1–123.5) 95.2 (86.7–106.9) 112.0 (101.5–123.3)
FEV1 (%pred) 104.7 (98.6–119.4) 90.5 (83.0–94.7) 78.7 (66.8–93.4)***
FEV1/FVC (%) 80.7 (74.9–85.2) 76.3 (73.5–78.7) 62.6 (54.0–64.7)****††
LAA score 0 (0–0) 0 (0–0) 5 (4–9) ***†††
GOLD Grade (1/2/3/4) NA NA 5/6/0/0
Exacerbations per year NA NA 0
Treatment
LABA NA NA 1
LAMA NA NA 5
LABA/LAMA NA NA 0
ICS NA NA 0
ICS/LABA NA NA 0
ICS/LABA/LAMA NA NA 0
Theophylline NA NA 0
Viable cell number per gram tissuea 7.4 × 106 (4.9 × 106–1.3 × 107) 1.1 × 107 (7.5 × 106–2.3 × 107) 1.1 × 107 (8.8 × 106–1.9 × 107)
Viability (%)b 88 (83–91) 90 (85–92) 88 (85–92)
Data are presented as the median (with interquartile ranges). Data were analysed with Chi-square test, Kruskal-Wallis test followed by Dunn’s multiple comparison
test or Mann-Whitney test
aViable cell number per gram tissue, the number of whole viable cells that were collected from 1 gram of lung tissues
bViability was evaluated with trypan blue staining
**P < 0.01, ***P < 0.001, ****P < 0.0001 compared with control never-smokers; ††P < 0.01, †††P < 0.001 compared with control ex-smokers
FVC forced vital capacity; FEV1, forced expiratory volume in 1 s; FEV1%pred % predicted values of FEV1; LAA, low attenuation area; GOLD Global Initiative for Chronic
Obstructive Lung Disease; LABA long-acting β agonists; LAMA long-acting muscarinic antagonists; ICS inhaled corticosteroids; NA not applicable
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by incubation with fluorescent dye-labeled NTHi. A
flow-cytometry analysis indicated that the anti-Siglec-1
blocking antibody significantly reduced the percentage
of NTHi-engulfed macrophages or the mean fluores-
cence intensity in macrophages (Fig. 3).
Discussion
Our data suggested two novel aspects for human alveo-
lar macrophages which may explain the compromised
phagocytic ability of the alveolar macrophages in COPD;
(i) the extracellular expression of plasma membrane-
Fig. 2 A decrease in cell surface expression of Siglec-1 on alveolar macrophages isolated from COPD lungs. Each antigen expression is shown as
(a) the percentage of positive alveolar macrophages expressing each phagocytic receptor to the total alveolar macrophages and (b) the ratio of
the geometric mean of the phagocytic receptor expression levels to the geometric mean of the corresponding isotype control in control never-
smokers (CNS, n = 11, white circles), control ex-smokers (CES, n = 9 grey circles) and COPD ex-smokers (COPD, n = 11, black circles). Data represent
median with interquartile ranges and were analysed with Kruskal-Wallis test followed by Dunn’s Multiple Comparison Test. *P < 0.05, **P < 0.01
compared with CNS; †P < 0.05 compared with CES. N.S. indicates “not significant”
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bound receptor for phagocytosis, Siglec-1, could be al-
tered under pathological conditions in COPD lung and
(ii) Siglec-1 was at least partially involved in the engulf-
ment of NTHi by human alveolar macrophages. Import-
antly we observed reduced Siglec-1 expression in mild-
to-moderate COPD subjects who had never experienced
exacerbations, indicating that phagocytic receptor
expression could be altered in early stages of COPD.
Siglecs (sialic acid-binding immunoglobulin (Ig)-like
lectins) are type 1 membrane proteins containing a hom-
ologous N-terminal V-set Ig-like domain that recognises
sialylated glycan, followed by variable numbers of C2 set
domains [18]. The Siglec family is classified into two
subfamilies: (i) Siglecs that are conserved across mam-
mals (Siglec-1, CD22, myelin-associated glycoprotein
and Siglec-15) and (ii) CD33-related Siglecs that are
variable across mammals and therefore are postulated to
have evolved rapidly [17]. Most Siglecs except for Siglec-
1 have cytoplasmic regions that mediate intracellular sig-
nalling and regulate innate and adaptive immunity.
CD22 and most CD33-related Siglecs have immunore-
ceptor tyrosine-based inhibitory motifs (ITIMs) in the
cytoplasmic domains [18], that suppress activation sig-
nals by recruiting cytoplasmic phosphatases containing a
Src homology 2 (SH2) domain [19]. Conversely a few
Siglecs, such as Siglec-14, coupled with immunoreceptor
tyrosine-based activating motifs (ITAMs)-bearing adap-
tors have the ability to activate immune cells via spleen
tyrosine kinase (Syk) [17].
Some emerging evidence from human genetic studies
has suggested that Siglecs are involved in pathogenesis
of COPD. Null allele of SIGLEC14 encoding immune-
activating Siglec-14 was associated with a reduced risk
of COPD exacerbation, possibly via suppression of pro-
inflammatory responses by inactivation of Syk [20]. An
integrative genomics approach utilising single nucleotide
Table 2 Correlation of clinical variables and phagocytosis-associated receptor expression on alveolar macrophages (univariable
analysis)
FcγRI MSR-1 Siglec-1
MFI ratio % positive MFI % positive MFI % positive
Age rs 0.2735 0.1550 0.1842 0.1776 0.3462 0.3061
P value 0.1365 0.4051 0.3213 0.3392 0.0564 0.0940
Gender rs −0.2666 −0.3258 − 0.1852 − 0.2889 −0.3184 −0.3184
P value 0.0737 0.3185 0.1149 0.0809 0.0809 0.0737
Smoking history (Pack-years) rs −0.3670 − 0.3645 − 0.3568 − 0.3817 − 0.5333 − 0.4753
P value 0.0423 0.0438 0.0488 0.0341 0.0020 0.0069
FEV1 (% pred) rs 0.4140 0.3533 0.5115 0.4459 0.4656 0.3958
P value 0.0206 0.0512 0.0033 0.0119 0.0083 0.0275
Low attenuation area scores rs −0.5358 −0.5577 −0.4564 −0.4945 −0.6778 −0.6440
P value 0.0019 0.0011 0.0099 0.0047 < 0.0001 < 0.0001
Bold denotes values P < 0.05
rs, Spearman rank correlation coefficient. FEV1, forced expiratory volume in 1 second. MFI, mean fluorescence intensity
MFI ratio indicates the ratio of receptor MFI to the corresponding FMO control MFI
% positive indicates the percentage of a receptor-positive alveolar macrophages to total alveolar macrophages
Table 3 Correlation of clinical variables and phagocytosis-associated receptor expression of alveolar macrophages (multiple linear
regression analysis)
FcγRI MSR-1 Siglec-1
MFI ratio % positive MFI % positive MFI % positive
Smoking history (Pack-years) Estimate 0.0116 −0.1288 0.0105 0.0514 −0.0193 −0.2747
P value 0.7078 0.6213 0.2396 0.8057 0.2488 0.2935
FEV1 (% pred) Estimate 0.0192 0.1153 0.0297 0.3519 −0.0057 −0.1107
P value 0.7158 0.7946 0.0548 0.3265 0.8397 0.8016
Low attenuation area scores Estimate −0.4466 −3.8890 −0.0002 −2.6940 −0.2661 −5.0410
P value 0.0731 0.0637 0.9982 0.1070 0.0463 0.0180
Estimate represents parameter estimate
Bold denotes values P < 0.05
FEV1, forced expiratory volume in one second. MFI, mean fluorescence intensity
MFI ratio indicates the ratio of receptor MFI to the corresponding FMO control MFI
% positive indicates the percentage of a receptor-positive alveolar macrophages to total alveolar macrophages
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polymorphisms (SNPs) on COPD phenotypes and a
genome-wide expression quantitative trait loci (eQTLs)
study on lung tissues revealed that CD22 was one of po-
tential causal genes for airflow limitation in patients with
COPD [21]. However, to our knowledge, there has been
no report showing a relationship between Siglec-1 and
COPD.
Siglec-1 (also known as sialoadhesin or CD169) prefer-
entially binds to α2,3-linked sialic acids [22, 23] and has
longer extracellular regions (i.e., 17 Ig domains) that lack
intracellular signalling motifs [24]. This unique structure
of Siglec-1 may enable extension of sialic acid-binding
sites outside the plasma membranes [25] and probably is
useful for recognition, capture and uptake of microbes
[17]. Siglec-1 is expressed by tissue macrophages and
has a critical role in recognition and clearance of sialy-
lated bacterial pathogens such as Neisseria meningitidis





Smoking (pack-years) 0.0 (0.0–0.0)
FVC (%pred) 114.7 (107.4–122.6)
FEV1 (%pred) 116.6 (113.1–119.8)
FEV1/FVC (%) 80.9 (75.7–83.0)
Viable cell number per gram tissuea 3.1 × 106 (2.9 × 106–3.8 × 106)
Viability (%)b 88 (77–90)
Data are presented as the median (with interquartile ranges)
aViable cell number per gram tissue, the number of whole viable cells that
were collected from one gram of lung tissues
bViability was evaluated with trypan blue staining
FVC forced vital capacity; FEV1 forced expiratory volume in 1 s; FEV1%pred %
predicted values of FEV1
Fig. 3 An anti-human Siglec-1 blocking antibody reduced engulfment of NTHi by human alveolar macrophages ex vivo. a Alveolar macrophages
isolated from resected lung tissues of control never smokers were incubated with heat-killed and pHrode dye-labeled NTHi in the presence of an
anti-human Siglec-1 blocking antibody or an isotype-matched control antibody. The bacterial engulfment was evaluated by flowcytometry. A
representative histogram of pHrode-dye fluorescence was shown. A grey line indicated cells without pHrode-labeled NTHi as a negative control.
A blue line showed cells treated with pHrode-labeled NTHi in the presence of an isotype-matched control antibody. A red line represented cells
treated with pHrode-labeled NTHi in the presence of an anti-human Siglec-1 blocking antibody. b Bacterial engulfment was quantified by the
percentage of NTHi-phagocytosed alveolar macrophages (upper panel) or by the mean fluorescence intensity (MFI) of pHrode-fluorescence in
alveolar macrophages (lower panel). Anti-Siglec-1 antibody treatment reduced the engulfment ability (N = 5, *P < 0.05, Paired t-test)
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[26], Campyrobacter jejuni [27] and group B streptococ-
cus [28]. In addition, Siglec-1 was required for proper
pro-inflammatory responses via tumour necrosis factor-
α and interferon (IFN)-β to eliminate C.jejuni that was
intravenously administered to mice [29]. NTHi is also
known to be a sialylated microbe and has genes en-
coding α2,3-sialyltransferase which adds sialic acids onto
its lipooligosaccharide [30, 31]. Considering a number of
evidence that NTHi is one of the most common bacteria
involved in bacterial colonisation and acute exacerbation
of COPD [32, 33], our data suggest that the reduced
capability of alveolar macrophage phagocytosis for NTHi
in COPD is due to the decrease in the extracellular
expression of Siglec-1.
Although accumulating studies observed the defective
phagocytosis of microbial pathogens including NTHi
and S.pneumoniae by alveolar macrophages in COPD
[4–6], there are few reports that identified molecular
mechanisms involved in the reduced phagocytic ability.
Bewley et al. recently reported that up-regulation of the
anti-apoptotic protein Mcl-1 and a failure to produce
mitochondrial ROS in alveolar macrophages of COPD
reduced intracellular killing of S.pneumoniae [34]. In
addition Harvey et al. reported that Nrf2 activation im-
proved the phagocytic ability for NTHi by increasing the
scavenger receptor MARCO in alveolar macrophages
derived from patients with COPD, though it has not
been examined whether MARCO protein expression is
down-regulated on the surface of alveolar macrophages
of COPD compared to control smokers [35]. Thus our
study firstly showed the possibility that an alteration of
plasma membrane-bound phagocytic receptors might be
a critical indicator for bacterial clearance of alveolar
macrophages under inflammatory conditions.
The multivariable linear regression analysis revealed
that the severity of pulmonary emphysema evaluated by
the low attenuation area score on chest CT scans was an
independent parameter associated with the decrease in
Siglec-1 on alveolar macrophages. Although type 1 inter-
feron was known to induce Siglec-1 protein expression
in patients with systemic sclerosis [36] or with human
immunodeficiency virus-1 [37], it has not been deter-
mined whether and how the Siglec-1 protein expression
is down-regulated during pathological processes. Thus
our finding provides new evidence of the reduced ex-
pression of Siglec-1 in COPD of which pathogenesis is
involved in chronic inflammation related to excessive
oxidative stress and would provide a rationale to investi-
gate molecular basis of upstream signalling pathways
negatively regulating Siglec-1 expression.
A large number of studies support the idea that Siglec-
1-expressing tissue macrophages have critical roles in
initiation of proper pro-inflammatory responses to
maintain homeostasis in viral infection, cancer and
autoimmune diseases [11, 17, 38]. This idea was further
validated by specific depletion of Siglec-1-positive mac-
rophages using Siglec-1-diphteria toxin receptor-
transgenic mice [39, 40]. Taken together with these
reports, our observation suggests that Siglec-1dim-neg
alveolar macrophages in COPD lungs might represent a
dysfunctional macrophage for innate host defence.
There are some limitations in our study. First, the
sample size of our flow-cytometric analysis was small
with only mild and moderate COPD, because the avail-
ability of resected lung tissues, especially from patients
with severe or very severe COPD, was limited. However
it is noteworthy that Siglec-1 was decreased even in the
early stages of COPD patients who had never experi-
enced acute exacerbation. Second, we did not investigate
a prospective cohort to determine whether patients with
COPD who have lower expression of Siglec-1 on their
alveolar macrophages exhibited higher bacterial colon-
isation or experienced more acute exacerbations. Further
functional studies with prospective larger cohorts are
needed to precisely define the roles of Siglec-1 on alveo-
lar macrophages in innate host defence under pathologic
conditions. Third, as we performed the in vitro phago-
cytosis assay with female control never smokers, we can-
not exclude a possibility that gender and smoking status
might affect this result. Fourth, because all patients in
this study had primary lung cancers, the presence of
tumour cells might suppress the expressions of phago-
cytic receptors and the ability of bacterial phagocytosis.
Although we used peripheral lung tissues distant from
tumor lesions, recent reports have indicated that cancer
cells might have a crosstalk with distant cells via extra-
cellular vesicles to inhibit anti-tumour immunity [41].
Fifth, small numbers of dendritic cells and monocytes
might be included in the phagocytosis assay, since we
did not exclude those cells using specific cell surface
markers in flow cytometry. Finally, although we observed
decreases in expression of FcγRI and MSR-1 in COPD
macrophages compared to CNS, we did not determine
whether Siglec-1dim-neg macrophages also lost expression
of FcγRI and MSR-1 or if decreased receptor expression
in COPD alveolar macrophages had less specificity. It
would be notable for a future study to evaluate multiple
receptor expression of alveolar macrophages in diseased
lungs.
Conclusions
We demonstrated that the extracellular expression of
Siglec-1 was decreased on alveolar macrophages of
COPD especially with pulmonary emphysema. Consider-
ing the involvement of Siglec-1 in NTHi phagocytosis by
human alveolar macrophages, our data shed light on the
importance of phagocytic receptors in alveolar macro-
phages in the pathogenesis of COPD.
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Additional file 1: Figure S1. CD206 is a marker for alveolar
macrophages in human lungs. A representative image of sorted FSChi/
SSChi/CD45+/CD206+ cells by Diff-Quick stain. An error bar, 50 μm. Repre-
sentative immunostaining for CD206 in lung tissues of control never-
smokers (CNS, upper images), control ex-smokers (CES, middle images)
and COPD ex-smokers (COPD, lower images). Right images are highly
magnified images from each rectangle in left, corresponding images.
Scale bars indicate 50 μm (left images), 25 μm (right images). Nuclei were
counterstained with haematoxylin (blue). Histograms of CD14 expression
on FSChi/SSChi/CD45+/CD206+ cells and on FSClo/SSClo/CD45+/CD206−
cells from human lung tissue lavages. FSChi/SSChi/CD45+/CD206+ cells
showed little expression of CD14. FSClo/SSClo/CD45+/CD206− cells con-
tained CD14-highly expressing cells corresponding monocytes (an arrow)
[1, 2]. Specific staining, red; isotype control, gray. Fig. S2. Siglec-1 expres-
sion in human alveolar macrophages. Representative immunostaining for
Siglec-1 in lung tissues of five control never-smokers (a left image) and a
negative control staining with only secondary antibody (a right image).
Scale bars indicate 50 μm. Table S1. Antibodies for flow cytometry. Table
S2. Isotype-matched control antibodies
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